Development of a Bacillus subtilis-based rotavirus vaccine

Clinical and Vaccine Immunology

Volumn 17, Issue 11, 2010, Pages 1647-1655

  Lee, Sangun ^a   Belitsky, Boris R ^b   Brinker, James P ^a   Kerstein, Kathryn O ^b   Brown, David W ^a   Clements, John D ^c   Keusch, Gerald T ^d   Tzipori, Saul ^a   Sonenshein, Abraham L ^b   Herrmann, John E ^a  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTEIN VP6; ROTAVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN 4; VIRUS PROTEIN 7;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACILLUS SUBTILIS; BACTERIAL SPORE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FECES ANALYSIS; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; INOCULATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAVIRUS INFECTION; VIRUS SHEDDING; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BACILLUS SUBTILIS; BACTERIAL TOXINS; CAPSID PROTEINS; CATTLE; CHOLERA TOXIN; DRUG CARRIERS; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI PROTEINS; FECES; FEMALE; GENETIC VECTORS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VIRUS SHEDDING;

EID: 78449236269     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00135-10     Document Type: Article

References (63)

1. Acheson, D. W. K., A. L. Sonenshein, J. M. Leong, and G. T. Keusch. 1997. Heat-stable spore-based vaccines: surface expression of invasin-cell wall fusion proteins in Bacillus subtilis, p. 179-184. In F. Brown, D. Burton, P. Doherty, J. Mekalanos, and E. Norrby (ed.), Vaccines 97. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
2. Barnes, A. G., V. Cerovic, P. S. Hobson, and L. S. Klavinskis. 2007. Bacillus subtilis spores: a novel microparticle adjuvant which can instruct a balanced Th1 and Th2 immune response to specific antigen. Eur. J. Immunol. 37:1538-1547.
3. Belitsky, B. R., and A. L. Sonenshein. 1998. Role and regulation of Bacillus subtilis glutamate dehydrogenase genes. J. Bacteriol. 180:6298-6305.
4. Bhandari, N., P. Sharma, R. I. Glass, P. Ray, H. Greenberg, S. Taneja, M. Saksena, C. D. Rao, J. R. Gentsch, U. Parashar, Y. Maldonado, R. L. Ward, and M. K. Bhan. 2006. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine 24:5817-5823.
5. Bhandari, N., P. Sharma, S. Taneja, T. Kumar, T. Rongsen-Chandola, M. B. Appaiahgari, A. Mishra, S. Singh, and S. Vrati. 2009. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J. Infect. Dis. 200:421-429.
6. Casula, G., and S. M. Cutting. 2002. Bacillus probiotics: spore germination in the gastrointestinal tract. Appl. Environ. Microbiol. 68:2344-2352.
7. Choi, A. H., M. Basu, M. M. McNeal, J. D. Clements, and R. L. Ward. 1999. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J. Virol. 73:7574-7581.
8. Ciarlet, M., S. E. Crawford, C. Barone, A. Bertolotti-Ciarlet, R. F. Ramig, M. K. Estes, and M. E. Conner. 1998. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J. Virol. 72:9233-9246.
9. Coffman, R. L., B. W. Seymour, D. A. Lebman, D. D. Hiraki, J. A. Christiansen, B. Shrader, H. M. Cherwinski, H. F. Savelkoul, F. D. Finkelman, M. W. Bond, et al. 1988. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102:5-28.
10. Conner, M. E., S. E. Crawford, C. Barone, and M. K. Estes. 1993. Rotavirus vaccine administered parenterally induces protective immunity. J. Virol. 67:6633-6641.
11. Corthesy, B., Y. Benureau, C. Perrier, C. Fourgeux, N. Parez, H. Greenberg, and I. Schwartz-Cornil. 2006. Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J. Virol. 80:10692-10699. (Pubitemid 44628915)
12. Costalonga, M., P. P. Cleary, L. A. Fischer, and Z. Zhao. 2009. Intranasal bacteria induce Th1 but not Treg or Th2. Mucosal Immunol. 2:85-95.
13. Dennehy, P. H. 2008. Rotavirus vaccines: an overview. Clin. Microbiol. Rev. 21:198-208.
14. Dharakul, T., L. Rott, and H. B. Greenberg. 1990. Recovery from chronic rotavirus infection in mice with severe combined immunodeficiency: virus clearance mediated by adoptive transfer of immune CD8+ T lymphocytes. J. Virol. 64:4375-4382.
15. Dickinson, B. L., and J. D. Clements. 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63:1617-1623.
16. Duc, L. H., H. A. Hong, N. Fairweather, E. Ricca, and S. M. Cutting. 2003. Bacterial spores as vaccine vehicles. Infect. Immun. 71:2810-2818.
17. Estes, M. K. 2001. Rotaviruses and their replication, p. 1447-1785. In D. M. Knipe and P. M. Howley (ed.), Fields virology. Lippincott Williams & Wilkins, Philadelphia, PA.
18. Ferreira, L. C., R. C. Ferreira, and W. Schumann. 2005. Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors. An. Acad. Bras. Cienc. 77:113-124.
19. Fouet, A., and A. L. Sonenshein. 1990. A target for carbon source-dependent negative regulation of the citB promoter of Bacillus subtilis. J. Bacteriol. 172:835-844.
20. Franco, M. A., C. Tin, and H. B. Greenberg. 1997. CD8+ T cells can mediate almost complete short-term and partial long-term immunity to rotavirus in mice. J. Virol. 71:4165-4170.
21. Franco, M. A., C. Tin, L. S. Rott, J. L. VanCott, J. R. McGhee, and H. B. Greenberg. 1997. Evidence for CD8+ T-cell immunity to murine rotavirus in the absence of perforin, fas, and gamma interferon. J. Virol. 71:479-486.
22. Galen, J. E., O. G. Gomez-Duarte, G. A. Losonsky, J. L. Halpern, C. S. Lauderbaugh, S. Kaintuck, M. K. Reymann, and M. M. Levine. 1997. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 15:700-708.
23. Gieni, R. S., Y. Fang, G. Trinchieri, D. T. Umetsu, and R. H. DeKruyff. 1996. Differential production of IL-12 in BALB/c and DBA/2 mice controls IL-4 versus IFN-gamma synthesis in primed CD4 lymphocytes. Int. Immunol. 8:1511-1520.
24. Grangette, C., H. Muller-Alouf, D. Goudercourt, M. C. Geoffroy, M. Turneer, and A. Mercenier. 2001. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect. Immun. 69:1547-1553.
25. Herrmann, J. E., S. C. Chen, E. F. Fynan, J. C. Santoro, H. B. Greenberg, and H. L. Robinson. 1996. DNA vaccines against rotavirus infections. Arch. Virol. Suppl. 12:207-215.
26. Herrmann, J. E., S. C. Chen, E. F. Fynan, J. C. Santoro, H. B. Greenberg, S. Wang, and H. L. Robinson. 1996. Protection against rotavirus infections by DNA vaccination. J. Infect. Dis. 174(Suppl. 1):S93-S97.
27. Herrmann, J. E., S. C. Chen, D. H. Jones, A. Tinsley-Bown, E. F. Fynan, H. B. Greenberg, and G. H. Farrar. 1999. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology 259:148-153.
28. Jaacks, K. J., J. Healy, R. Losick, and A. D. Grossman. 1989. Identification and characterization of genes controlled by the sporulation-regulatory gene spo0H in Bacillus subtilis. J. Bacteriol. 171:4121-4129.
29. Jiang, B., J. R. Gentsch, and R. I. Glass. 2008. Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 26:6754-6758.
30. Jin, S., P. A. Levin, K. Matsuno, A. D. Grossman, and A. L. Sonenshein. 1997. Deletion of the Bacillus subtilis isocitrate dehydrogenase gene causes a block at stage I of sporulation. J. Bacteriol. 179:4725-4732.
31. Lanata, C. F., K. Midthun, R. E. Black, B. Butron, A. Huapaya, M. E. Penny, G. Ventura, A. Gil, M. Jett-Goheen, and B. L. Davidson. 1996. Safety, immunogenicity, and protective efficacy of one and three doses of the tetravalent rhesus rotavirus vaccine in infants in Lima, Peru. J. Infect. Dis. 174:268-275.
32. Lewis, D. J., Z. Huo, S. Barnett, I. Kromann, R. Giemza, E. Galiza, M. Woodrow, B. Thierry-Carstensen, P. Andersen, D. Novicki, G. Del Giudice, and R. Rappuoli. 2009. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 4:e6999.
33. Linhares, A. C., Y. B. Gabbay, J. D. Mascarenhas, R. B. de Freitas, C. S. Oliveira, N. Bellesi, T. A. Monteiro, Z. Lins-Lainson, F. L. Ramos, and S. A. Valente. 1996. Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil. Bull. World Health Organ. 74:491-500.
34. Loy, A. L., G. Allison, C. F. Arias, and N. K. Verma. 1999. Immune response to rotavirus VP4 expressed in an attenuated strain of Shigella flexneri. FEMS Immunol. Med. Microbiol. 25:283-288.
35. Madhi, S. A., N. A. Cunliffe, D. Steele, D. Witte, M. Kirsten, C. Louw, B. Ngwira, J. C. Victor, P. H. Gillard, B. B. Cheuvart, H. H. Han, and K. M. Neuzil. 2010. Effect of human rotavirus vaccine on severe diarrhea in African infants. N. Engl. J. Med. 362:289-298.
36. McNeal, M. M., M. N. Rae, and R. L. Ward. 1997. Evidence that resolution of rotavirus infection in mice is due to both CD4 and CD8 cell-dependent activities. J. Virol. 71:8735-8742.
37. McNeal, M. M., S. C. Stone, M. Basu, J. A. Bean, J. D. Clements, B. A. Hendrickson, A. H. Choi, and R. L. Ward. 2006. Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA. Virology 346:338-347.
38. McNeal, M. M., J. L. VanCott, A. H. Choi, M. Basu, J. A. Flint, S. C. Stone, J. D. Clements, and R. L. Ward. 2002. CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J. Virol. 76:560-568.
39. Middleton, R., and A. Hofmeister. 2004. New shuttle vectors for ectopic insertion of genes into Bacillus subtilis. Plasmid 51:238-245. (Pubitemid 38510370)
40. Murphy, T. V., P. M. Gargiullo, M. S. Massoudi, D. B. Nelson, A. O. Jumaan, C. A. Okoro, L. R. Zanardi, S. Setia, E. Fair, C. W. LeBaron, M. Wharton, and J. R. Livengood. 2001. Intussusception among infants given an oral rotavirus vaccine. N. Engl. J. Med. 344:564-572.
41. Nicholson, W. L., N. Munakata, G. Horneck, H. J. Melosh, and P. Setlow. 2000. Resistance of Bacillus endospores to extreme terrestrial and extraterrestrial environments. Microbiol. Mol. Biol. Rev. 64:548-572.
42. Norton, P. M., J. M. Wells, H. W. Brown, A. M. Macpherson, and R. W. Le Page. 1997. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine 15:616-619.
43. Oggioni, M. R., A. Ciabattini, A. M. Cuppone, and G. Pozzi. 2003. Bacillus spores for vaccine delivery. Vaccine 21(Suppl. 2):S96-S101.
44. Ogier, A., M. A. Franco, A. Charpilienne, J. Cohen, P. Pothier, and E. Kohli. 2005. Distribution and phenotype of murine rotavirus-specific B cells induced by intranasal immunization with 2/6 virus-like particles. Eur. J. Immunol. 35:2122-2130.
45. O'Neal, C. M., S. E. Crawford, M. K. Estes, and M. E. Conner. 1997. Rotavirus virus-like particles administered mucosally induce protective immunity. J. Virol. 71:8707-8717.
46. Paccez, J. D., H. D. Nguyen, W. B. Luiz, R. C. Ferreira, M. E. Sbrogio-Almeida, W. Schuman, and L. C. Ferreira. 2007. Evaluation of different promoter sequences and antigen sorting signals on the immunogenicity of Bacillus subtilis vaccine vehicles. Vaccine 25:4671-4680.
47. Parashar, U. D., and R. I. Glass. 2009. Rotavirus vaccines - early success, remaining questions. N. Engl. J. Med. 360:1063-1065.
48. Parashar, U. D., E. G. Hummelman, J. S. Bresee, M. A. Miller, and R. I. Glass. 2003. Global illness and deaths caused by rotavirus disease in children. Emerg. Infect. Dis. 9:565-572.
49. Perez-Schael, I., M. J. Guntinas, M. Perez, V. Pagone, A. M. Rojas, R. Gonzalez, W. Cunto, Y. Hoshino, and A. Z. Kapikian. 1997. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N. Engl. J. Med. 337:1181-1187.
50. Perez, C. A., C. Eichwald, O. Burrone, and D. Mendoza. 2005. Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice. J. Appl. Microbiol. 99:1158-1164.
51. Sambrook, J., E. F. Fritsch, and T. J. Maniatis. 1989. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
52. Schwartz-Cornil, I., Y. Benureau, H. Greenberg, B. A. Hendrickson, and J. Cohen. 2002. Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J. Virol. 76:8110-8117.
53. Sonenshein, A. L., J. A. Hoch, and R. Losick. 1993. Bacillus subtilis and other gram positive bacteria: biochemistry, physiology, and molecular genetics, p. 3-16, 917-937. In A. L. Sonenshein, J. A. Hoch, and R. Losick (ed.), Bacillus subtilis and other Gram-positive bacteria. American Society of Microbiology, Washington, DC.
54. Spinosa, M. R., T. Braccini, E. Ricca, M. De Felice, L. Morelli, G. Pozzi, and M. R. Oggioni. 2000. On the fate of ingested Bacillus spores. Res. Microbiol. 151:361-368.
55. Uyen, N. Q., H. A. Hong, and S. M. Cutting. 2007. Enhanced immunisation and expression strategies using bacterial spores as heat-stable vaccine delivery vehicles. Vaccine 25:356-365.
56. van Pinxteren, L. A., M. G. Bruce, I. Campbell, A. Wood, C. J. Clarke, A. Bellman, B. Morein, and D. R. Snodgrass. 1999. Effect of oral rotavirus/iscom vaccines on immune responses in gnotobiotic lambs. Vet. Immunol. Immunopathol. 71:53-67.
57. Vashishtha, V. M., A. Kalra, T. J. John, N. Thacker, and R. K. Agarwal. 2008. Recommendations of 2nd National Consultative Meeting of Indian Academy of Pediatrics (IAP) on polio eradication and improvement of routine immunization. Indian Pediatr. 5:367-378.
58. Wang, L., J. A. Huang, H. S. Nagesha, S. C. Smith, A. Phelps, I. Holmes, J. C. Martyn, P. J. Coloe, and P. R. Reeves. 1999. Bacterial expression of the major antigenic regions of porcine rotavirus VP7 induces a neutralizing immune response in mice. Vaccine 17:2636-2645.
59. Yang, K., S. Wang, K. O. Chang, S. Lu, L. J. Saif, H. B. Greenberg, J. P. Brinker, and J. E. Herrmann. 2001. Immune responses and protection obtained with rotavirus VP6 DNA vaccines given by intramuscular injection. Vaccine 19:3285-3291.
60. Yanisch-Perron, C., J. Vieira, and J. Messing. 1985. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33:103-119.
61. Yansura, D. G., and D. J. Henner. 1984. Use of the Escherichia coli lac repressor and operator to control gene expression in Bacillus subtilis. Proc. Natl. Acad. Sci. U. S. A. 81:439-443.
62. Yuan, L., A. Geyer, D. C. Hodgins, Z. Fan, Y. Qian, K. O. Chang, S. E. Crawford, V. Parreno, L. A. Ward, M. K. Estes, M. E. Conner, and L. J. Saif. 2000. Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs. J. Virol. 74:8843-8853.
63. Yuan, L., S. Y. Kang, L. A. Ward, T. L. To, and L. J. Saif. 1998. Antibody-secreting cell responses and protective immunity assessed in gnotobiotic pigs inoculated orally or intramuscularly with inactivated human rotavirus. J. Virol. 72:330-338.